Literature DB >> 16831410

Enzymatic and non-enzymatic antioxidant status in stage (III) human oral squamous cell carcinoma and treated with radical radio therapy: influence of selenium supplementation.

Narchonai Elango1, Shila Samuel, Panneerselvam Chinnakkannu.   

Abstract

BACKGROUND: Oxidative stress is implicated in oral carcinogenesis and has been found to be aggravated during radiotherapy. A great deal of attention has been focused on the possible therapeutic implications of selenium as a potent antioxidant. We determined whether selenium supplementation to radiation treated oral cancer patients render improvement in the antioxidant status against oxidative stress.
METHOD: Blood samples were collected from stage (III) oral cancer patients before initiating radiotherapy (Group B) (n=63) and this group is bifurcated into Group C-patients given radiotherapy alone (n=27) and Group D-patients given radiotherapy and supplemented with selenium (400 mug/day for 6 months) (n=36). Both Group C and D were followed up for 6 months. We evaluated the plasma selenium concentration, non-enzymatic system including GSH, vitamins E, C, A and ceruloplasmin and enzymatic antioxidant system including superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase, glucose-6-phosphate dehydrogenase.
RESULTS: The concentrations of selenium, all non-enzymatic antioxidants and the activities of enzymatic antioxidants were found to be lowered in oral cancer patients (Group B), compared to normal (Group A) (p<0.05). Similar decrease in the concentration of selenium and antioxidants status was observed in radiotherapy group (Group C) (p<0.05). On the contrary, selenium group (Group D) showed marked increase in the concentrations of selenium and antioxidant status at 6 months compared to radiation group (Group C) (p<0.05).
CONCLUSION: The observed result represents the antioxidant property of selenium through the improvement of antioxidant defense system. Selenium supplementation could be of great interest in protecting cells against oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16831410     DOI: 10.1016/j.cca.2006.05.021

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  4 in total

Review 1.  Selenium for alleviating the side effects of chemotherapy, radiotherapy and surgery in cancer patients.

Authors:  G Dennert; M Horneber
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19

2.  Modulators of erythrocyte glutathione peroxidase activity in healthy adults: an observational study.

Authors:  Kiriaque Barra Ferreira Barbosa; Ana Carolina Pinheiro Volp; José Luiz Marques-Rocha; Sônia Machado Rocha Ribeiro; Iñigo Navarro-Blasco; Mária Ángeles Zulet; J Alfredo Martínez; Josefina Bressan
Journal:  Redox Rep       Date:  2014-06-20       Impact factor: 4.412

Review 3.  Selenium and lung cancer: a systematic review and meta analysis.

Authors:  Heidi Fritz; Deborah Kennedy; Dean Fergusson; Rochelle Fernandes; Kieran Cooley; Andrew Seely; Stephen Sagar; Raimond Wong; Dugald Seely
Journal:  PLoS One       Date:  2011-11-04       Impact factor: 3.240

Review 4.  Updates on clinical studies of selenium supplementation in radiotherapy.

Authors:  Irma M Puspitasari; Rizky Abdulah; Chiho Yamazaki; Satomi Kameo; Takashi Nakano; Hiroshi Koyama
Journal:  Radiat Oncol       Date:  2014-05-29       Impact factor: 3.481

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.